PERTH, Australia – Biotech and med-tech firms are booming in Australia and 87 percent of companies surveyed said they expect to grow this year, according to a survey conducted by AusBiotech.
PERTH, Australia – Sydney-based gene therapy company Benitec Biopharma Ltd. saw its stock more than double following a global out-licensing deal with Axovant Sciences Ltd. valued at $187.5 million for its DNA-directed RNA interference (ddRNAi) therapy BB-301.
PERTH, Australia – Sydney-based gene therapy company Benitec Biopharma Ltd. saw its stock more than double following a global out-licensing deal with Axovant Sciences Ltd. valued at $187.5 million for its DNA-directed RNA interference (ddRNAi) therapy BB-301.
PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials after reporting solid results in two cohorts of patients in its phase I trial in steroid-resistant graft-vs.-host disease (GvHD).
PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials after reporting solid results in two cohorts of patients in its phase I trial in steroid-resistant graft-vs.-host disease.
